Related Experiment Video
Updated: Jan 10, 2026
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
MicroRNA-21 is a potential therapeutic agent targeting Tgfbi and mitigating high-fat-diet-induced liver disease and
Urmila Jagtap1,2, Anan Quan1,2, Yuho Ono1
1Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA.
Abstract:
Liver disease, including hepatocellular carcinoma (HCC), is a major global health concern, claiming approximately 2 million lives worldwide annually, yet curative treatments remain elusive. In this study, we aimed to investigate the role of microRNA-21-5p (miR-21) in metabolic-dysfunction-associated steatotic liver disease (MASLD), metabolic-associated steatohepatitis (MASH), and HCC within the context of a Western choline-deficient (CD) high-fat diet (HFD) and offer potential therapeutic insights. We found that reduced miR-21 levels correlated with liver-disease progression in wild-type (WT) mice fed on CD-HFD, while miR-21-knockout mice showed exacerbated metabolic dysfunction, including obesity, hepatomegaly, hyperglycemia, insulin resistance, steatosis, fibrosis, and HCC. Our study reveals that miR-21 plays a protective role in metabolic syndrome and in the progression of liver disease to cancer. miR-21 directly targets Transforming growth factor beta-induced (Tgfbi), a gene also known to be significantly upregulated and a potential oncogene in HCC. Further, our study showed that intervention with the administration of an miR-21 mimic in WT livers effectively improves insulin sensitivity, steatosis, fibrosis, Tgfbi expression, and tumor burden in CD-HFD conditions. These findings indicate that miR-21 could serve as an effective strategy to delay or prevent liver disease in HFD environments.
Insights
MicroRNA-21 (miR-21) protects against liver disease progression, including cancer, by targeting the oncogene Tgfbi. Restoring miR-21 levels may prevent or delay liver conditions linked to metabolic dysfunction and high-fat diets.
Area of Science:
- Hepatology
- Molecular Biology
- Metabolic Syndrome Research
Background:
- Liver disease, including hepatocellular carcinoma (HCC), poses a significant global health challenge with limited curative options.
- Metabolic-dysfunction-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) are increasing health concerns, often linked to dietary factors.
- MicroRNAs (miRNAs) are emerging as critical regulators in liver disease pathogenesis.
Purpose of the Study:
- To investigate the role of microRNA-21-5p (miR-21) in the progression of MASLD, MASH, and HCC.
- To explore the therapeutic potential of miR-21 in the context of a Western choline-deficient (CD) high-fat diet (HFD).
- To identify direct molecular targets of miR-21 involved in liver disease progression.
Main Methods:
- Utilized wild-type (WT) and miR-21-knockout mouse models fed a CD-HFD.
- Analyzed metabolic parameters, liver pathology (steatosis, fibrosis, hepatomegaly), hyperglycemia, and insulin resistance.
- Investigated miR-21's direct targeting of Transforming growth factor beta-induced (Tgfbi) and assessed therapeutic effects of an miR-21 mimic.
Main Results:
- Reduced miR-21 levels correlated with liver disease progression in WT mice on CD-HFD.
- miR-21 knockout mice exhibited worsened metabolic dysfunction and accelerated liver disease and HCC development.
- miR-21 directly targets and downregulates Tgfbi, a gene upregulated in HCC.
- Administration of an miR-21 mimic improved metabolic parameters, reduced steatosis and fibrosis, and decreased tumor burden in CD-HFD mice.
Conclusions:
- miR-21 plays a crucial protective role in preventing metabolic syndrome and the progression of liver disease to cancer.
- Targeting Tgfbi via miR-21 modulation represents a potential therapeutic strategy for liver diseases associated with metabolic dysfunction.
- Restoring miR-21 levels offers a promising approach to delay or prevent liver disease in high-fat diet environments.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF